Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects With Type 1 Diabetes

• ClinicalTrials.gov Identifier: NCT02660827
• Recruitment Status: Completed
• First Posted: January 21, 2016
• Results First Posted: January 11, 2019
• Last Update Posted: January 26, 2022
• Sponsor: Medtronic Diabetes
• Information provided by (Responsible Party): Medtronic Diabetes

Study Description

Brief Summary:

This study is a single-arm, multi-center, Home and Hotel Clinical Investigation in pediatric subjects with type 1 diabetes on insulin pump therapy. The purpose of this study is to demonstrate that the closed loop algorithm is safe as part of the overall system, and to assess the PLGM feature in 7-13 years old subjects.

Condition or disease	Intervention/treatment	Phase
Type 1 Diabetes	Device: Insulin Pump	Not Applicable

Detailed Description:

The study will proceed as follows:

Run-in Period - General:

A total of up to 200 subjects (age 2-13) will be enrolled at up to 15 investigational centers (14 in the US, 1 EMEA) in order to reach 120 subjects who will complete the HCL study.

Study Period - At Home:

Following the two week run-in period using the Study Pump (670G), all subjects (age 2-13) will participate in a 3-month study period.

Study Period - Hotel Study Subjects (age 7-13) will participate in a Hotel study (6 days, 5 nights), with the remainder of the study period to be spent at home. Subjects 2-6 years of age are not required to participate in a hotel study. Instead, they will participate in an out-of-home study for 5 consecutive days, 4-6 hours per day.

Continued Access Program Subjects will be given the opportunity to extend use of their study devices for a period of up to 3 years . If subjects choose to participate in the continuation period, they will retain the study devices at the end of study period visit or receive them back in the event they have been returned to study staff already.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 151 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects With Type 1 Diabetes
• Actual Study Start Date: April 18, 2016
• Actual Primary Completion Date: November 28, 2018
• Actual Study Completion Date: February 1, 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: Hybrid closed loop; All subjects will be wearing the MMT-670G insulin pump, using it with the closed loop algorithm	Device: Insulin Pump; Closed Loop Algorithm; Other Name: MMT-670G

Outcome Measures

Primary Outcome Measures :

1. Age 2-13 Years Old Subjects Change in A1C [ Time Frame: Baseline and end of 3-month study period ]
   Descriptive analysis of change in A1C from baseline to end of 3-month study period

Secondary Outcome Measures :

1. Age 2-13 Years Old Subjects Mean Change in % of Time in Euglycemia (70-180 mg/dL) [ Time Frame: baseline and 3 months ]
   mean change in % of time in Euglycemia (70-180 mg/dL) from baseline to 3 months study period
2. Age 2-13 Years Old Subjects Mean Change in % of Time in Hyperglycemia (> 180 mg/dL) [ Time Frame: baseline and 3 months ]
   mean change in % of time in hyperglycemia (> 180 mg/dL) from baseline to 3 months study period
3. Age 2-13 Years Old Subjects Mean Change in % of Time in Hypoglycemia (<70 mg/dL) [ Time Frame: baseline and 3 months ]
   mean change in % of time in hypoglycemia (< 70 mg/dL) from baseline to 3 months study period
4. Age 2-13 Years Old - Number of Severe Hypoglycemic Event [ Time Frame: 3 months ]
   Number of severe hypoglycemic events occurred during 3-month study period.
5. Age 2-13 Years Old - Number of Diabetic Ketoacidosis (DKA) Event [ Time Frame: 3 months ]
   Number of Diabetic Ketoacidosis (DKA) events occurred during 3-month study period.
6. Age 7-13 Years Old Subjects PLGM Performance - Event Rate Without Hypoglycemia at YSI-FST <=65 mg/dL [ Time Frame: Up to 12 hours after the start of PLGM period ]
   Event rate without Hypoglycemia at YSI-FST <=65 mg/dL among 105 subjects who underwent the PLGM experiments. The event rate without hypoglycemia is the number of experiments without hypoglycemia/total number of experiments and hypoglycemic events are defined based on the occurrence of 2 or more continuous YSI-FST <= 65mg/dL during in-clinic procedures.

Eligibility Criteria

• Ages Eligible for Study: 2 Years to 13 Years (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

General Inclusion Criteria

1. Subject is age 2-13 years at time of screening
2. Subject has a clinical diagnosis of type 1 diabetes for 1 year or more as determined via medical record or source documentation by an individual qualified to make a medical diagnosis

3. Subject age 2-6 years has a clinical diagnosis of type 1 diabetes for 3 months or more as determined via medical record or source documentation by an individual qualified to make a medical diagnosis

   Study-specific inclusion criteria

4. Subject must have a minimum daily insulin requirement (Total Daily Dose) of greater than or equal to 8 units
5. Subjects 7-13: Subjects and their parent(s)/guardian(s) are willing to participate in an overnight visit at the end of the run-in period.
6. Subject 7-13 years of age and their parent(s)/guardian(s) are willing to participate in a hotel study for the specified duration of hotel stay.
7. Subject 2-6 years of age and their parent(s)/guardian(s) are willing to participate in an extended visit during the study period to perform Frequent Sample Testing.
8. Subject must have companion 18 years or older who will sleep in the same dwelling place every night during the study period. This requirement may be verified by subject report at screening visit.
9. Subject is willing to perform ≥ 4 finger stick blood glucose measurements daily
10. Subject is willing to perform required sensor calibrations
11. Subject is willing to wear the system continuously throughout the study
12. Subject has a Glycosylated hemoglobin (A1C) value less than 10.0% (as processed by Central Lab) at time of screening visit Note: All HbA1C blood specimens will be sent to and tested by a NGSP certified Central Laboratory. A1C testing must follow National Glycohemoglobin Standardization Program (NGSP) standards.
13. Subject has TSH in the normal range OR if the TSH is out of normal reference range the Free T3 is below or within the lab's reference range and Free T4 is within the normal reference range.
14. Subject 7 -13 years of age has had pump therapy for greater than 6 months prior to screening (with or without CGM experience)
15. Subject 2-6 years of age has had pump therapy for greater than 90 days prior to screening (with or without CGM experience)
16. Subjects and their parent(s)/guardian(s) are willing to upload data from the study pump; must have Internet access and a computer system that meets the requirements for uploading the study pump
17. If subject has celiac disease, it has been adequately treated as determined by the investigator

18. Subjects and their parent(s)/guardian(s) are willing to take one of the following insulins and can financially support the use of either of the 2 insulin preparations throughout the course of the study (i.e. co-payments for insulin with insurance or able to pay full amount)

    • Humalog® (insulin lispro injection)
    • NovoLog® (insulin aspart)
19. Subjects and their parent(s)/guardian(s)/companions must be able to speak and be literate in English as verified by the investigator

Exclusion Criteria:

1. Subject has a history of 2 or more episodes of severe hypoglycemia, which resulted in any the following during the 6 months prior to screening:

   1. Medical assistance (i.e. Paramedics, Emergency Room ( ER) or Hospitalization)
   2. Coma
   3. Seizures
2. Subject is unable to tolerate tape adhesive in the area of sensor placement
3. Subject has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection)
4. Females who are sexually active and able to conceive will be excluded if they are not using an effective method of contraception and do not agree to continue using an effective method of contraception for the duration of the study as determined by investigator.
5. Subject has a cardiovascular condition which the investigator determines should exclude the subject, i.e. ventricular rhythm disturbance, hypertrophic cardiomyopathy
6. Subject is being treated for hyperthyroidism at time of screening
7. Subject has diagnosis of adrenal insufficiency
8. Subject 7-13 years of age has had DKA in the 6 months prior to screening visit.
9. Subject 2-6 years of age has had DKA in the 3 months prior to screening visit
10. Subject has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8 weeks from time of screening visit, or plans to take any oral, injectable, or IV glucocorticoids during the course of the study
11. Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks
12. Subject 7-13 years of age has been hospitalized or has visited the ER in the 6 months prior to screening resulting in a primary diagnosis of uncontrolled diabetes
13. Subject 2-6 years of age has been hospitalized or has visited the ER in the 3 months prior to screening resulting in a primary diagnosis of uncontrolled diabetes
14. Subject is currently abusing illicit drugs
15. Subject is currently abusing marijuana.
16. Subject is currently abusing prescription drugs
17. Subject is currently abusing alcohol
18. Subject is using pramlintide (Symlin), DPP-4 inhibitor, liraglutide (Victoza or other GLP-1 agonists), metformin, canagliflozin (Invokana or other SGLT2 inhibitors) at time of screening
19. Subject has a history of visual impairment which would not allow subject to participate in the study and perform all study procedures safely, as determined by the investigator
20. Subject has elective surgery planned that requires general anesthesia during the course of the study
21. Subject has a sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening
22. Subject plans to receive red blood cell transfusion or erythropoietin over the course of study participation
23. Subject diagnosed with current eating disorder such as anorexia or bulimia
24. Subject has been diagnosed with chronic kidney disease that results in chronic anemia
25. Subject has a hematocrit that is below the normal reference range of lab used.
26. Subject is on dialysis
27. Subject has serum creatinine of >2 mg/dL.

Contacts and Locations

Locations

United States, California

AMCR Institute

Escondido, California, United States, 92025

Stanford Hospital and Clinics

Palo Alto, California, United States, 94305

SoCal Diabetes

Torrance, California, United States, 90505

United States, Colorado

Barbara Davis Center

Aurora, Colorado, United States, 80045

United States, Florida

Nemours Children's Clinic

Jacksonville, Florida, United States, 32207

University of South Florida - USF Health

Tampa, Florida, United States, 33620

United States, Georgia

Atlanta Diabetes Associates

Atlanta, Georgia, United States, 30318

United States, Idaho

Rocky Mountain Diabetes and Osteoporosis Center

Idaho Falls, Idaho, United States, 83404

United States, Indiana

Indiana University

Indianapolis, Indiana, United States, 46202

United States, Michigan

University of Michigan

Ann Arbor, Michigan, United States, 48109

Israel

Sheba Medical Center

Tel Aviv, Israel

Sponsors and Collaborators

Medtronic Diabetes

  Study Documents (Full-Text)

Documents provided by Medtronic Diabetes:

Study Protocol  [PDF] January 29, 2019

Statistical Analysis Plan  [PDF] October 18, 2017

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Forlenza GP, Ekhlaspour L, DiMeglio LA, Fox LA, Rodriguez H, Shulman DI, Kaiserman KB, Liljenquist DR, Shin J, Lee SW, Buckingham BA. Glycemic outcomes of children 2-6 years of age with type 1 diabetes during the pediatric MiniMed 670G system trial. Pediatr Diabetes. 2022 May;23(3):324-329. doi: 10.1111/pedi.13312. Epub 2022 Jan 31.

Forlenza GP, Pinhas-Hamiel O, Liljenquist DR, Shulman DI, Bailey TS, Bode BW, Wood MA, Buckingham BA, Kaiserman KB, Shin J, Huang S, Lee SW, Kaufman FR. Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes. Diabetes Technol Ther. 2019 Jan;21(1):11-19. doi: 10.1089/dia.2018.0264. Epub 2018 Dec 26.

• Responsible Party: Medtronic Diabetes
• ClinicalTrials.gov Identifier: NCT02660827
• Other Study ID Numbers: CEP 302
• First Posted: January 21, 2016
• Results First Posted: January 11, 2019
• Last Update Posted: January 26, 2022
• Last Verified: January 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Additional relevant MeSH terms:

Diabetes Mellitus; Diabetes Mellitus, Type 1; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Autoimmune Diseases; Immune System Diseases; Insulin; Hypoglycemic Agents; Physiological Effects of Drugs